TERT promoter mutations in bladder cancer affect patient survival and disease recurrence through modification by a common polymorphism
Open accessThe DOI matches its Crossref record; 37 of the 37 references it cites were found in a registry or an index.
Abstract
Significance: This study shows that the telomerase reverse transcriptase ( TERT ) promoter mutations, which create de novo E-twenty six/ternary complex factors (Ets/TCF) transcription binding sites, besides being the most common somatic genetic lesions, influence both survival and disease recurrence in bladder cancer patients. The effect of the TERT promoter mutations on both survival and recurrence is modified by a common polymorphism within the preexisting Ets binding site in the TERT promoter. The data were supported by the results from reporter assays carried out in two urothelial carcinoma cell lines. The findings of the study suggest that the TERT promoter mutations in conjunction with the common polymorphism have potential of being used as clinical biomarkers in bladder cancer.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hallmarks of Cancer: The Next Generation
Hanahan, D., & Weinberg, R. A. (2011) · Cell · doi:10.1016/j.cell.2011.02.013 · Cited by 66,590
Vogelstein, B., Papadopoulos, N., Velculescu, V. E., Zhou, S., Diaz, L. A., & Kinzler, K. W. (2013) · Science · doi:10.1126/science.1235122 · Cited by 7,863
An integrated map of genetic variation from 1,092 human genomes
The 1000 Genomes Project Consortium (2012) · Nature · doi:10.1038/nature11632 · Cited by 7,711
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345
Epidemiology and Risk Factors of Urothelial Bladder Cancer
Burger, M., Catto, J. W. F., Dalbagni, G., Grossman, H. B., Herr, H., Karakiewicz, P., Kassouf, W., Kiemeney, L. A., La Vecchia, C., Shariat, S., et al. (2013) · European Urology · doi:10.1016/j.eururo.2012.07.033 · Cited by 2,164
Highly Recurrent TERT Promoter Mutations in Human Melanoma
Huang, F. W., Hodis, E., Xu, M. J., Kryukov, G. V., Chin, L., & Garraway, L. A. (2013) · Science · doi:10.1126/science.1229259 · Cited by 1,816
TERT Promoter Mutations in Familial and Sporadic Melanoma
Horn, S., Figl, A., Rachakonda, P. S., Fischer, C., Sucker, A., Gast, A., Kadel, S., Moll, I., Nagore, E., Hemminki, K., et al. (2013) · Science · doi:10.1126/science.1230062 · Cited by 1,799 · cited 6×
“The core TERT promoter region 343 bp (from the position −278 to +65 from ATG start site) was screened for mutations using PCR and Sanger sequencing (Table S4) as described (7).”
BackgroundMethodInfluentialSelf-citationKillela, P. J., Reitman, Z. J., Jiao, Y., Bettegowda, C., Agrawal, N., Diaz, L. A., Friedman, A. H., Friedman, H., Gallia, G. L., Giovanella, B. C., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1303607110 · Cited by 1,368
The discovery of receptor tyrosine kinases: targets for cancer therapy
Gschwind, A., Fischer, O. M., & Ullrich, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1360 · Cited by 1,227 · cited 1×
“The altered pathways in the both variants of bladder cancer have been a subject of research for targeted therapy (17, 18).”
BackgroundDulak, A. M., Stojanov, P., Peng, S., Lawrence, M. S., Fox, C., Stewart, C., Bandla, S., Imamura, Y., Schumacher, S. E., Shefler, E., et al. (2013) · Nature Genetics · doi:10.1038/ng.2591 · Cited by 735
Cited by
Advances in bladder cancer biology and therapy
Tran, L., Xiao, J.-F., Agarwal, N., Duex, J. E., & Theodorescu, D. (2021) · Nature Reviews Cancer · doi:10.1038/s41568-020-00313-1 · Cited by 735
Roles of telomeres and telomerase in cancer, and advances in telomerase-targeted therapies
Jafri, M. A., Ansari, S. A., Alqahtani, M. H., & Shay, J. W. (2016) · Genome Medicine · doi:10.1186/s13073-016-0324-x · Cited by 716
The transcription factor GABP selectively binds and activates the mutant TERT promoter in cancer
Bell, R. J. A., Rube, H. T., Kreig, A., Mancini, A., Fouse, S. D., Nagarajan, R. P., Choi, S., Hong, C., He, D., Pekmezci, M., et al. (2015) · Science · doi:10.1126/science.aab0015 · Cited by 566
Role of non-coding sequence variants in cancer
Khurana, E., Fu, Y., Chakravarty, D., Demichelis, F., Rubin, M. A., & Gerstein, M. (2016) · Nature Reviews Genetics · doi:10.1038/nrg.2015.17 · Cited by 468
Protein Glycosylation and Tumor Microenvironment Alterations Driving Cancer Hallmarks
Peixoto, A., Relvas-Santos, M., Azevedo, R., Santos, L. L., & Ferreira, J. A. (2019) · Frontiers in Oncology · doi:10.3389/fonc.2019.00380 · Cited by 334
TERT—Regulation and Roles in Cancer Formation
Dratwa, M., Wysoczańska, B., Łacina, P., Kubik, T., & Bogunia-Kubik, K. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.589929 · Cited by 311
Understanding TERT Promoter Mutations: A Common Path to Immortality
Bell, R. J. A., Rube, H. T., Xavier-Magalhães, A., Costa, B. M., Mancini, A., Song, J. S., & Costello, J. F. (2016) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-16-0003 · Cited by 307
Telomeres and Telomere Length: A General Overview
Srinivas, N., Rachakonda, S., & Kumar, R. (2020) · Cancers · doi:10.3390/cancers12030558 · Cited by 304
Self-citationTERT promoter mutations and telomerase reactivation in urothelial cancer
Borah, S., Xi, L., Zaug, A. J., Powell, N. M., Dancik, G. M., Cohen, S. B., Costello, J. C., Theodorescu, D., & Cech, T. R. (2015) · Science · doi:10.1126/science.1260200 · Cited by 292
Fredriksson, N. J., Ny, L., Nilsson, J. A., & Larsson, E. (2014) · Nature Genetics · doi:10.1038/ng.3141 · Cited by 289
Mechanisms of human telomerase reverse transcriptase (hTERT) regulation: clinical impacts in cancer
Leão, R., Apolónio, J. D., Lee, D., Figueiredo, A., Tabori, U., & Castelo-Branco, P. (2018) · Journal of Biomedical Science · doi:10.1186/s12929-018-0422-8 · Cited by 265
Understanding the Molecular Genetics of Basal Cell Carcinoma
Pellegrini, C., Maturo, M., Di Nardo, L., Ciciarelli, V., Gutiérrez García-Rodrigo, C., & Fargnoli, M. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18112485 · Cited by 242
TERT promoter mutations in cancer development
Heidenreich, B., Rachakonda, P. S., Hemminki, K., & Kumar, R. (2014) · Current Opinion in Genetics & Development · doi:10.1016/j.gde.2013.11.005 · Cited by 238
Self-citationKircher, M., Xiong, C., Martin, B., Schubach, M., Inoue, F., Bell, R. J. A., Costello, J. F., Shendure, J., & Ahituv, N. (2019) · Nature Communications · doi:10.1038/s41467-019-11526-w · Cited by 234
Reactivation of telomerase in cancer
Akincilar, S. C., Unal, B., & Tergaonkar, V. (2016) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-016-2146-9 · Cited by 222
“This mechanism is in contrast to the two highly recurrent Tert mutations which generate an ETS/TCF binding site [112].”
BackgroundTERT promoter mutations in gliomas, genetic associations and clinico-pathological correlations
Labussière, M., Di Stefano, A. L., Gleize, V, Boisselier, B., Giry, M., Mangesius, S., Bruno, A., Paterra, R., Marie, Y., Rahimian, A., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.538 · Cited by 202
“Our data showed that TERTp-mut is generally associated with poorer outcome in high-grade gliomas, consistently with previous data, on glioma (Killela et al, 2013, 2014), and other tumours (Rachakonda et al, 2013).”
BackgroundResultInfluentialHuang, D.-S., Wang, Z., He, X.-J., Diplas, B. H., Yang, R., Killela, P. J., Meng, Q., Ye, Z.-Y., Wang, W., Jiang, X.-T., et al. (2015) · European Journal of Cancer · doi:10.1016/j.ejca.2015.03.010 · Cited by 193
“restricted to melanoma and occur frequently in several tumour types, including gliomas [4,5], liposarcomas [4], urothelial carcinomas [4,6–9] and hepatocellular carcinomas [4,10].”
BackgroundRegulation of mutant TERT by BRAF V600E/MAP kinase pathway through FOS/GABP in human cancer
Liu, R., Zhang, T., Zhu, G., & Xing, M. (2018) · Nature Communications · doi:10.1038/s41467-018-03033-1 · Cited by 178
Telomeres and telomerase in oncogenesis (Review)
Trybek, T., Kowalik, A., Góźdź, S., & Kowalska, A. (2020) · Oncology Letters · doi:10.3892/ol.2020.11659 · Cited by 119
Frequency of TERT promoter mutations in primary tumors of the liver
Quaas, A., Oldopp, T., Tharun, L., Klingenfeld, C., Krech, T., Sauter, G., & Grob, T. J. (2014) · Virchows Archiv · doi:10.1007/s00428-014-1658-7 · Cited by 70
Wang, J., Dayem Ullah, A. Z., & Chelala, C. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky057 · Cited by 35
“Moreover, TERT promoter mutations significantly correlate with survival and disease recurrence in bladder cancer, demonstrating the clinical significance for noncoding mutations (8).”
BackgroundMultiple Faces of the Glioblastoma Microenvironment
Șovrea, A. S., Boșca, B., Melincovici, C. S., Constantin, A.-M., Crintea, A., Mărginean, M., Dronca, E., Jianu, M. E., Suflețel, R., Gonciar, D., et al. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23020595 · Cited by 26
“TERT promoter mutations in GBMs are associated with a worse prognosis than IDH wild-type GBMs [21,29].”
Background
Metadata
- Authors
- Rachakonda, P. S., Hosen, I., de Verdier, P. J., Fallah, M., Heidenreich, B., Ryk, C., Wiklund, N. P., Steineck, G., Schadendorf, D., Hemminki, K., & Kumar, R.
- Venue
- Proceedings of the National Academy of Sciences
- Published
- 2013-10-07
- Volume
- 110
- Issue
- 43
- Pages
- 17426-17431
- ISSN
- 0027-8424 (ISSN-L)
- 1091-6490
- OpenAlex
- W2008493391
- Cited by
- 340
- References
- 37
- FWCI
- 32.93
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.